ClinicalTrials.gg
RecruitingNCT07421102Updated Jul 30, 2026

Pilot of Mailing Buprenorphine

An Early Phase 1 interventional study of strategy of mailing buprenorphine in Opioid Use Disorder, sponsored by Medical University of South Carolina. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Medical University of South Carolina · Early Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Opioid-Related Disorders by Medical University of South Carolina — 7 open to participants now, 7 under way, none of them phase 3. Opioid-Related Disorders · Medical University of South Carolina.

Planned enrollment
10th of 15
20 · median 24
Started
2026
with 3 others
Phase 1
4 of 15
1 open now
Registered
14th of 15
by date

Among the 15 studies in Opioid-Related Disorders by Medical University of South Carolina, this one is the 10th largest by planned enrollment, is one of 4 that started in 2026, is one of 4 in phase 1, and was the 14th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

7 of the 15 studies in Opioid-Related Disorders by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Opioid-Related Disorders by Medical University of South Carolina, or all of them as a file.
02

Study summary

This pilot study evaluates the feasibility, acceptability, and preliminary effectiveness of mailing buprenorphine to individuals with opioid use disorder (OUD) following medical hospitalization. The intervention aims to improve retention in treatment by overcoming barriers such as transportation and pharmacy access.

Read the detailed description

This single-center, hybrid type 3 pilot study will enroll 20 medically hospitalized patients with OUD who are initiated on buprenorphine during their inpatient stay. Participants will be discharged with a supply of buprenorphine and enrolled in the MOUD Direct Delivery (MOUDDD) Program, which mails monthly refills directly to their homes. The study will evaluate the feasibility (successful delivery), acceptability (patient-reported measures), and preliminary effectiveness (treatment retention at 1, 3, and 6 months) of mailing buprenorphine. Secondary outcomes include quality of life, adherence, overdose, and healthcare utilization. The intervention leverages existing mail-order pharmacy protocols and aims to inform scalable strategies for improving transitions of care and retention in OUD treatment.

03

Conditions studied

  • Opioid Use Disorder

Keywords

  • mailing buprenorphine
  • transitions of care
  • opioid use disorder
  • barriers to buprenorphine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18
  • English-speaking
  • Diagnosed with OUD and initiated on buprenorphine during hospitalization
  • Discharging to a South Carolina address with a stable mailbox
  • Access to phone or computer

Exclusion criteria

Exclusion Criteria:

  • Active psychosis or suicidal ideation
  • Severe medical or neurocognitive impairment
  • Pending incarceration
05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    Mailed Medications

    There is no comparison arm. This pilot study evaluates the feasibility of mailing medications to patients.

    Other: strategy of mailing buprenorphine

Interventions

  • Otherstrategy of mailing buprenorphine

    This study examines the feasibility and preliminary effectiveness of mailing buprenorphine to overcome barriers such as transportation to obtaining buprenorphine from a pharmacy.

06

What researchers measure

Primary outcomes

  1. Feasibility (successful receipt)

    Successful delivery and receipt of medication defined by self-report and phone/text/video confirmation to receive code

    Time frame: From enrollment to the end of the study at 6 months

  2. Successful receipt

    Feasibility is defined by the successful receipt of the buprenorphine prescriptions in the mail by the intended participants. Successful receipt defined by self-report and phone/text/video confirmation from participant. Delivery failure is defined as delay in receipt of medication by \>48 hours by the mail delivery service.

    Time frame: From enrollment to the end of study at 6 months.

  3. Retention in treatment

    Preliminary effectiveness of mailing buprenorphine will be measured by retention in treatment. This is defined by the proportion of participants retained in buprenorphine treatment at 1,3, and 6 months after discharge.

    Time frame: time of study enrollment to end of study at 6 months

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.

Of 55 non-industry phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 9 months is below that.

Counting every sponsor, half of 79 studies reached it within 19 months; a quarter within 9 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 19, 2026
StartActual
Apr 8, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07421102
Responsible party
Allison Smith (Associate Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Feb 19, 2026
Start date
Apr 8, 2026
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jul 30, 2026

Study contacts

Allison Smith, MD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion